| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.96  |
1-year : | 9.3 |
| Resists | First : | 6.82 |
Second : | 7.96 |
| Pivot price | 5.6  |
|||
| Supports | First : | 5.59 |
Second : | 4.83 |
| MAs | MA(5) : | 5.49 |
MA(20) : | 5.65 |
| MA(100) : | 4.25 |
MA(250) : | 3.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.4 |
D(3) : | 37.4 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 12.14 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed below upper band by 33.8%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.81 - 5.83 | 5.83 - 5.85 |
| Low: | 5.14 - 5.16 | 5.16 - 5.19 |
| Close: | 5.61 - 5.65 | 5.65 - 5.69 |
Sat, 29 Nov 2025
Is EVAX stock a contrarian buy - Market Movement Recap & Expert Verified Stock Movement Alerts - moha.gov.vn
Fri, 21 Nov 2025
Evaxion Biotech Increases Share Capital Following Warrant Exercise - MSN
Thu, 20 Nov 2025
Evaxion (NASDAQ: EVAX) Reports Protective Preclinical Data for CMV Program EVX-V1 - Stock Titan
Fri, 07 Nov 2025
Evaxion (NASDAQ: EVAX) reports EVX-01 T-cell induction in Phase 2 melanoma at SITC - Stock Titan
Thu, 06 Nov 2025
Evaxion (NASDAQ: EVAX) reports $4.6M net income as MSD option lifts $7.5M revenue - Stock Titan
Fri, 31 Oct 2025
Evaxion (NASDAQ: EVAX) to hold Q3 results call and business update on November 6 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 8 (M) |
| Shares Float | 179 (M) |
| Held by Insiders | 18.3 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 637 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.6 |
| Profit Margin | -70.9 % |
| Operating Margin | 40.3 % |
| Return on Assets (ttm) | -25.7 % |
| Return on Equity (ttm) | -65 % |
| Qtrly Rev. Growth | 148.3 % |
| Gross Profit (p.s.) | 0.92 |
| Sales Per Share | 0.92 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.48 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 6.39 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|